Highlights include adjuvant bisphosphonates, endocrine therapy, treatment of HER2-positive breast cancer, and genomic scores for predicting risk for recurrence of ductal carcinoma in situ.
Presentations at the 2011 San Antonio Breast Cancer Symposium (SABCS; December 6–10, 2011) encompassed bisphosphonates as adjuvant therapy, use of biological mechanisms to enhance endocrine therapy, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and genomic assays for ductal carcinoma in situ (DCIS). Key findings are summarized below; for more information, readers are encouraged to visit the SABCS website.
Benefits of Bisphosphonates
Several reports focused on the role of bisphosphonates for lowering recurrence risk in patients with early breast cancer. The ABSCG-12 trial of adjuvant endocrine therapy (ovarian suppression plus tamoxifen or anastrozole) with or without zoledronic acid (ZA) was updated with…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)